X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SUN PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SUN PHARMA IPCA LABS/
SUN PHARMA
 
P/E (TTM) x 42.1 25.1 167.8% View Chart
P/BV x 3.2 3.7 88.1% View Chart
Dividend Yield % 0.2 0.6 25.4%  

Financials

 IPCA LABS   SUN PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
SUN PHARMA
Mar-17
IPCA LABS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs643842 76.4%   
Low Rs503572 87.8%   
Sales per share (Unadj.) Rs254.4131.6 193.3%  
Earnings per share (Unadj.) Rs16.132.7 49.1%  
Cash flow per share (Unadj.) Rs29.838.0 78.4%  
Dividends per share (Unadj.) Rs1.003.50 28.6%  
Dividend yield (eoy) %0.20.5 35.3%  
Book value per share (Unadj.) Rs194.6152.7 127.4%  
Shares outstanding (eoy) m126.202,399.26 5.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.35.4 41.9%   
Avg P/E ratio x35.721.6 164.8%  
P/CF ratio (eoy) x19.218.6 103.3%  
Price / Book Value ratio x2.94.6 63.6%  
Dividend payout %6.210.7 58.1%   
Avg Mkt Cap Rs m72,3001,696,877 4.3%   
No. of employees `00013.317.5 75.9%   
Total wages/salary Rs m6,96049,023 14.2%   
Avg. sales/employee Rs Th2,413.518,028.3 13.4%   
Avg. wages/employee Rs Th523.22,798.8 18.7%   
Avg. net profit/employee Rs Th152.44,479.5 3.4%   
INCOME DATA
Net Sales Rs m32,106315,784 10.2%  
Other income Rs m2266,232 3.6%   
Total revenues Rs m32,332322,016 10.0%   
Gross profit Rs m4,448100,893 4.4%  
Depreciation Rs m1,73012,648 13.7%   
Interest Rs m2413,998 6.0%   
Profit before tax Rs m2,70390,479 3.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m67512,116 5.6%   
Profit after tax Rs m2,02878,462 2.6%  
Gross profit margin %13.931.9 43.4%  
Effective tax rate %25.013.4 186.5%   
Net profit margin %6.324.8 25.4%  
BALANCE SHEET DATA
Current assets Rs m17,340329,537 5.3%   
Current liabilities Rs m9,559178,870 5.3%   
Net working cap to sales %24.247.7 50.8%  
Current ratio x1.81.8 98.5%  
Inventory Days Days10079 127.0%  
Debtors Days Days5783 68.3%  
Net fixed assets Rs m20,779204,766 10.1%   
Share capital Rs m2522,399 10.5%   
"Free" reserves Rs m24,499363,997 6.7%   
Net worth Rs m24,553366,397 6.7%   
Long term debt Rs m3,51714,361 24.5%   
Total assets Rs m39,595614,102 6.4%  
Interest coverage x12.223.6 51.7%   
Debt to equity ratio x0.10 365.5%  
Sales to assets ratio x0.80.5 157.7%   
Return on assets %5.713.4 42.7%  
Return on equity %8.321.4 38.6%  
Return on capital %10.524.8 42.2%  
Exports to sales %48.60-   
Imports to sales %14.20-   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,571NA-   
Fx inflow Rs m15,61744,118 35.4%   
Fx outflow Rs m5,82824,484 23.8%   
Net fx Rs m9,79019,634 49.9%   
CASH FLOW
From Operations Rs m2,76470,822 3.9%  
From Investments Rs m-1,432-42,216 3.4%  
From Financial Activity Rs m-1,591-22,854 7.0%  
Net Cashflow Rs m-2596,107 -4.2%  

Share Holding

Indian Promoters % 45.9 63.7 72.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 5.1 222.2%  
FIIs % 25.3 23.0 110.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 8.3 209.6%  
Shareholders   36,892 133,026 27.7%  
Pledged promoter(s) holding % 2.1 0.5 403.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 20, 2018 03:35 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS